New Zealand Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2356126
  • December 2012
  • Region: New Zealand
  • 77 pages
  • Business Monitor International


  • Company Profiles
  • Douglas Pharmaceuticals
  • MORE

BMI View: Low growth potential in New Zealand's pharmaceutical market will attract risk-averse investors. However, we note that regulatory delays in funding new medicines will hinder patients' access to pharmaceuticals, constituting a downside risk for drug companies looking to sell their products in the country.

Headline Expenditure Forecasts:

- Pharmaceuticals: NZD1.35bn (US$1.07bn) in 2011 to NZD1.36bn (US$1.04bn) in 2012;
+1.2% in local currency and -2.7% in US dollar terms.

- Healthcare: NZD19.34bn (US$15.29bn) in 2011 to NZD19.93bn (US$15.14bn) in 2012; +3.0
%in local currency and -1.0% in US dollar terms.

- Medical Devices: NZD814mn (US$644mn) in 2011 to NZD832mn (US$632mn) in 2012;
+2.2% in local currency and -1.8% in US dollar terms.

Risk/Reward Rating:

New Zealand was ranked 10th out of 18 pharmaceutical markets surveyed in the Asia region in Q113. Its score is dragged down by a low industry rewards score, due to its small and relatively low-growth potential market, and a low industry risks score because of its regulatory processes.

In terms of Rewards, New Zealand is rated highly thanks to a stable economic and political READ MORE >

Note: Product cover images may vary from those shown


  • Company Profiles
  • Douglas Pharmaceuticals
  • MORE

Executive Summary 5

SWOT Analysis 7

New Zealand Pharmaceuticals & Healthcare Industry SWOT 7

New Zealand Political SWOT 8

New Zealand Economic SWOT 8

New Zealand Business Environment SWOT 9

Risk/Reward Ratings 10

Pharmaceuticals Risk/Reward Ratings 10
Table: Asia Pacific – Regional Risk/Reward Ratings Q113 10

Rewards 11

Risks 11

New Zealand – Market Summary 13

Regulatory Regime 14

Intellectual Property Protection 14

Pricing And Reimbursement 15

Reimbursement Funding 18
Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn) 19
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn) 20
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010 21

Recent Regulatory Developments 21

Industry Developments 23

Epidemiology 23

Healthcare Sector 24

Infrastructure 26

Services 26

Workforce 28
Table: Regional Ranking of Projected Physicians, 2017 28
Table: Projected Physicians, 2012-2017 29

Latest Figures 29

Active Medical Practitioners, 2005-2010 29

Distribution Channels 31

Drug Wholesaling 31

Leading Wholesalers 31

Drug Retailing 31

Leading Pharmacy Chains 32
Table: Pharmacybrands Stores by Company & Region, 2010 33

Radius Pharmacy 33

Research and Development (R&D) 33

Clinical Trials Sector 34

Medical Devices 36

Medical Devices Classes In New Zealand 36

Industry Forecast Scenario 38

Pharmaceutical Market Forecast 38
Table: Pharmaceutical Sales Indicators 2008-2016 39

Healthcare Market Forecast 40
Table: Healthcare Expenditure Indicators 2008-2016 40
Table: Healthcare Governmental Indicators 2008-2016 41
Table: Healthcare Private Indicators 2008-2016 41

Key Growth Factors – Macroeconomic Forecast 43
Table: Economic Activity 46

Prescription Drug Market Forecast 47
Table: Prescription Drug Sales Indicators 2008-2016 47

Patented Drug Market Forecast 48
Table: Patented Drug Market Indicators 2008-2016 49

Generic Drug Market Forecast 50
Table: Generic Drug Sales Indicators 2008-2016 50

OTC Drug Market Forecast 51
Table: OTC Medicine Sales Indicators 2008-2016 52

Pharmaceutical Trade Forecast 53
Table: Exports and Imports Indicators 2008-2016 54

Medical Device Market Forecast 55
Table: Medical Devices Sales Indicators 2008-2016 55

Other Healthcare Data 57

Key Risks To BMI's Forecast Scenario 58

Competitive Landscape 59

Pharmaceutical Industry 59
Table: Licensed Medicine Manufacturers, 2008 59

Company Developments 61

Company Profiles 63

Douglas Pharmaceuticals 63

New Zealand Pharmaceuticals 65

Demographic Outlook 67

Population By Age Group 68

Population By Age Group 69

Key Population Ratios 70

Rural and Urban Population 70

Glossary 71

BMI Methodology 73

How We Generate Our Pharmaceutical Industry Forecasts 73

Risk/Reward Ratings Methodology 74

Ratings Overview 74
Table: Pharmaceutical Business Environment Indicators 75

Weighting 76
Table: Weighting Of Components 76

Note: Product cover images may vary from those shown

Company Profiles
Douglas Pharmaceuticals
New Zealand Pharmaceuticals

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Corporation
  • Merck & Co., Inc.